Charles Xing

545 total citations
20 papers, 424 citations indexed

About

Charles Xing is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Charles Xing has authored 20 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Charles Xing's work include Monoclonal and Polyclonal Antibodies Research (12 papers), CAR-T cell therapy research (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Charles Xing is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), CAR-T cell therapy research (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Charles Xing collaborates with scholars based in United States and China. Charles Xing's co-authors include James Leonard, Robert M. Jones, Zhi‐Liang Chu, David J. Unett, Christopher J. Carroll, Jay M. Short, William J. Boyle, Gerhard Frey, Guilherme Rocha Pereira and Beatriz Fioravanti and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Charles Xing

19 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles Xing United States 8 211 185 113 98 88 20 424
Michael Lückmann Denmark 10 268 1.3× 148 0.8× 123 1.1× 103 1.1× 42 0.5× 16 403
Nicole Bernad France 12 183 0.9× 37 0.2× 55 0.5× 206 2.1× 124 1.4× 30 394
Erik C. Joly Canada 6 304 1.4× 275 1.5× 310 2.7× 67 0.7× 25 0.3× 10 540
Suma I. Shimuta Brazil 14 285 1.4× 70 0.4× 19 0.2× 112 1.1× 29 0.3× 34 479
Patricio Atanes United Kingdom 11 135 0.6× 91 0.5× 124 1.1× 42 0.4× 20 0.2× 19 286
Amy E. Monaghan United Kingdom 8 222 1.1× 34 0.2× 55 0.5× 83 0.8× 23 0.3× 12 361
Lars Dan Johansen Denmark 8 245 1.2× 99 0.5× 69 0.6× 126 1.3× 34 0.4× 8 416
Wen Chiy Liew Singapore 2 178 0.8× 33 0.2× 50 0.4× 78 0.8× 20 0.2× 2 294
Margit MacDougall United States 9 161 0.8× 140 0.8× 111 1.0× 65 0.7× 33 0.4× 12 273
Gerd Krause Germany 11 325 1.5× 120 0.6× 38 0.3× 155 1.6× 8 0.1× 13 463

Countries citing papers authored by Charles Xing

Since Specialization
Citations

This map shows the geographic impact of Charles Xing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Xing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Xing more than expected).

Fields of papers citing papers by Charles Xing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Xing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Xing. The network helps show where Charles Xing may publish in the future.

Co-authorship network of co-authors of Charles Xing

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Xing. A scholar is included among the top collaborators of Charles Xing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Xing. Charles Xing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chang, Hwai Wen, Gerhard Frey, Jing Wang, et al.. (2025). Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate. mAbs. 17(1). 2490078–2490078. 6 indexed citations
2.
Chang, Hwai Wen, Jing Wang, Charles Xing, et al.. (2025). Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate. PubMed. 8(2). 145–156. 3 indexed citations
3.
4.
Xing, Charles, et al.. (2024). Abstract 744: Novel conditionally active biologic (CAB) tetravalent T-cell engagers targeting solid tumors. Cancer Research. 84(6_Supplement). 744–744. 1 indexed citations
5.
6.
Lucas, Matthew C., Charles Xing, Cathy Chang, et al.. (2023). Abstract 1871: Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors. Cancer Research. 83(7_Supplement). 1871–1871. 1 indexed citations
7.
Frey, Gerhard, Jing Wang, Charles Xing, et al.. (2023). Abstract 1541: NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety. Cancer Research. 83(7_Supplement). 1541–1541. 2 indexed citations
8.
Chang, Hwai Wen, Gerhard Frey, Charles Xing, et al.. (2021). Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. Proceedings of the National Academy of Sciences. 118(9). 37 indexed citations
9.
Wang, Jing, Charles Xing, Matthew C. Lucas, et al.. (2021). Abstract 1870: Novel conditionally active bispecific T cell engagers targeting solid tumors. Cancer Research. 81(13_Supplement). 1870–1870. 1 indexed citations
10.
Wang, Jing, Charles Xing, Matthew C. Lucas, et al.. (2020). Abstract 5698: Novel conditionally active bispecific T cell engagers targeting solid tumors. Cancer Research. 80(16_Supplement). 5698–5698. 2 indexed citations
11.
Wang, Jing, Charles Xing, Matthew C. Lucas, et al.. (2020). Abstract 4560: Conditionally active biologics (CAB): A novel class of molecules targeting solid tumors. Cancer Research. 80(16_Supplement). 4560–4560. 4 indexed citations
12.
Chang, Cathy, Gerhard Frey, Leslie L. Sharp, et al.. (2019). Abstract 356: Novel conditionally active biologic (CAB) antibody targeting EpCAM demonstrates anti-tumor efficacy in vivo. Cancer Research. 79(13_Supplement). 356–356. 1 indexed citations
13.
Sharp, Leslie L., Cathy Chang, Gerhard Frey, et al.. (2019). Abstract 2708: Potent CAB CTLA4 antibody to reduce immune side effects and toxicities associated with single-agent and combination cancer immuno therapies. Cancer Research. 79(13_Supplement). 2708–2708. 1 indexed citations
14.
Sharp, Leslie L., Cathy Chang, Gerhard Frey, et al.. (2018). Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC. Cancer Research. 78(13_Supplement). 827–827. 16 indexed citations
15.
Sharp, Leslie L., Cathy Chang, Gerhard Frey, et al.. (2018). Abstract 833: Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC. Cancer Research. 78(13_Supplement). 833–833. 15 indexed citations
16.
Unett, David J., Joel Gatlin, Todd L. Anthony, et al.. (2013). Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration. Journal of Pharmacology and Experimental Therapeutics. 347(3). 645–659. 45 indexed citations
17.
Semple, Graeme, Albert Ren, Beatriz Fioravanti, et al.. (2011). Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorganic & Medicinal Chemistry Letters. 21(10). 3134–3141. 53 indexed citations
18.
Chu, Zhi‐Liang, Christopher J. Carroll, Ruoping Chen, et al.. (2009). N-Oleoyldopamine Enhances Glucose Homeostasis through the Activation of GPR119. Molecular Endocrinology. 24(1). 161–170. 103 indexed citations
19.
Semple, Graeme, Beatriz Fioravanti, Guilherme Rocha Pereira, et al.. (2008). Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119. Journal of Medicinal Chemistry. 51(17). 5172–5175. 117 indexed citations
20.
Xing, Charles, et al.. (2001). [Effects of heat stress on DA mediated PI signal transduction system in rat striatum].. PubMed. 14(2). 116–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Lückmann Breakdown of academic impact, for papers by Nicole Bernad Breakdown of academic impact, for papers by Erik C. Joly Breakdown of academic impact, for papers by Suma I. Shimuta Breakdown of academic impact, for papers by Patricio Atanes Breakdown of academic impact, for papers by Amy E. Monaghan Breakdown of academic impact, for papers by Lars Dan Johansen Breakdown of academic impact, for papers by Wen Chiy Liew Breakdown of academic impact, for papers by Margit MacDougall Breakdown of academic impact, for papers by Gerd Krause
Rankless by CCL
2026